Across TCGA pan-cancer cohorts, MAML3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAML3 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAML3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAML3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where MAML3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.671	0.266	<.001	39	view →
LUAD	DFS	Median	II,III,IV	0.883	0.217	.004	14	view →
CCRCC	DFS	Quartile	All	1.000	0.827	.009	4	view →
GBM	DFS	Quartile	All	0.668	0.891	.021	2	view →
LSCC	OS	Median	All	1.000	0.767	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MAML3 tumor-vs-normal RNA expression · all MAML3 data types